Regulation of radiosensitivity by 4-methylumbelliferone via the suppression of interleukin-1 in fibrosarcoma cells. 2019

Ryo Saga, and Kazuki Hasegawa, and Kosho Murata, and Mitsuru Chiba, and Toshiya Nakamura, and Kazuhiko Okumura, and Eichi Tsuruga, and Yoichiro Hosokawa
Department of Radiation Sciences, Graduate School of Health Sciences, Hirosaki University, Hirosaki, Aomori 036-8564, Japan.

Tumor recurrence and distant metastasis following radiotherapy, which can lead to poor prognosis, are caused by residual cancer cells that acquire radioresistance. Chemotherapy or a combination of targeted inhibitors can potentially enhance radiation sensitivity and prevent metastasis. It was previously reported that co-administration of the hyaluronan synthesis inhibitor 4-methylumbelliferone (4-MU) enhanced the lethality of X-ray irradiation in HT1080 human fibrosarcoma cells and decreased their invasiveness to a greater extent than either treatment alone. To clarify the molecular basis of these effects, the present study conducted mRNA expression profiling by cDNA microarray to identify the signaling pathways that are altered under this combination treatment. The activation state of the signaling pathways was classified by z-scores in the Ingenuity Pathway Analysis. The results revealed that the pro-inflammatory cytokines interleukin (IL)-6 and IL-8 were activated by 2 Gy X-ray irradiation, an effect that was abolished by co-administration of 4-MU. Similar trends were observed for the upstream signaling component IL-1. These results indicate that the radiosensitivity of fibrosarcoma cells is improved by suppressing inflammation through the administration of 4-MU.

UI MeSH Term Description Entries

Related Publications

Ryo Saga, and Kazuki Hasegawa, and Kosho Murata, and Mitsuru Chiba, and Toshiya Nakamura, and Kazuhiko Okumura, and Eichi Tsuruga, and Yoichiro Hosokawa
May 2020, Journal of orthopaedic research : official publication of the Orthopaedic Research Society,
Ryo Saga, and Kazuki Hasegawa, and Kosho Murata, and Mitsuru Chiba, and Toshiya Nakamura, and Kazuhiko Okumura, and Eichi Tsuruga, and Yoichiro Hosokawa
September 2007, Cell biology international,
Ryo Saga, and Kazuki Hasegawa, and Kosho Murata, and Mitsuru Chiba, and Toshiya Nakamura, and Kazuhiko Okumura, and Eichi Tsuruga, and Yoichiro Hosokawa
October 2009, Oncology reports,
Ryo Saga, and Kazuki Hasegawa, and Kosho Murata, and Mitsuru Chiba, and Toshiya Nakamura, and Kazuhiko Okumura, and Eichi Tsuruga, and Yoichiro Hosokawa
April 1995, Journal of the National Cancer Institute,
Ryo Saga, and Kazuki Hasegawa, and Kosho Murata, and Mitsuru Chiba, and Toshiya Nakamura, and Kazuhiko Okumura, and Eichi Tsuruga, and Yoichiro Hosokawa
January 2017, Oncology letters,
Ryo Saga, and Kazuki Hasegawa, and Kosho Murata, and Mitsuru Chiba, and Toshiya Nakamura, and Kazuhiko Okumura, and Eichi Tsuruga, and Yoichiro Hosokawa
January 1992, International archives of allergy and immunology,
Ryo Saga, and Kazuki Hasegawa, and Kosho Murata, and Mitsuru Chiba, and Toshiya Nakamura, and Kazuhiko Okumura, and Eichi Tsuruga, and Yoichiro Hosokawa
October 2004, Comparative biochemistry and physiology. Toxicology & pharmacology : CBP,
Ryo Saga, and Kazuki Hasegawa, and Kosho Murata, and Mitsuru Chiba, and Toshiya Nakamura, and Kazuhiko Okumura, and Eichi Tsuruga, and Yoichiro Hosokawa
January 1995, Journal of clinical laboratory analysis,
Ryo Saga, and Kazuki Hasegawa, and Kosho Murata, and Mitsuru Chiba, and Toshiya Nakamura, and Kazuhiko Okumura, and Eichi Tsuruga, and Yoichiro Hosokawa
October 1991, Blood,
Ryo Saga, and Kazuki Hasegawa, and Kosho Murata, and Mitsuru Chiba, and Toshiya Nakamura, and Kazuhiko Okumura, and Eichi Tsuruga, and Yoichiro Hosokawa
September 1994, Journal of neurosurgery,
Copied contents to your clipboard!